Biocorrx INC

BioCorRx Inc. has acquired a 12.15% stake in its subsidiary, BioCorRx Pharmaceuticals, from key executives and directors in a stock-for-stock exchange.

BioCorRx Inc. has entered into a Securities Purchase Agreement to raise $350,000 by issuing common stock and warrants to accredited investors.

BioCorRx Pharmaceuticals Inc. acquires Lucemyra, an FDA-approved medication for opioid withdrawal, from USWM, LLC to expand its addiction treatment offerings.

BioCorRx Inc. has replaced its independent auditor, Marcum LLP, with M&K CPAS, PLLC, effective July 8, 2024.

BioCorRx Inc. reports the resignation of two board members, Brady Granier and Harsha Murthy, effective March 31, 2024, and April 2, 2024, respectively.

BioCorRx Inc. reported a 59% increase in revenue for Q1 2026, driven by Lucemyra sales, but continued to incur net losses.

BioCorRx Inc. reported a significant revenue increase in Q3 2025, driven by the Lucemyra acquisition, despite ongoing net losses and a substantial working capital deficit, raising going concern doubts.

BioCorRx Inc. reported a significant revenue increase driven by a new acquisition but continues to face substantial doubt about its ability to continue as a going concern, compounded by a new legal challenge to its grant funding.

BioCorRx Inc. reports a significant revenue increase in Q1 2025 driven by the acquisition of Lucemyra, despite ongoing concerns about its ability to continue as a going concern.

BioCorRx Inc. reports a net loss for the third quarter of 2024, with ongoing research and development efforts and financial restructuring activities.

BioCorRx Inc. reported a significant decrease in revenue for the second quarter of 2024, coupled with increased operating expenses, leading to a larger net loss compared to the same period last year.

BioCorRx Inc. reported a reduced net loss and a significant revenue increase in 2025, driven by a new acquisition and substantial grant funding, despite ongoing going concern doubts and internal control weaknesses.

BioCorRx Inc. reports its annual results for the fiscal year ended December 31, 2024, detailing financial performance, research and development activities, and strategic initiatives.

BioCorRx Inc. announces its 2023 financial results, highlighting a net loss but also securing a significant $11 million grant for the development of a methamphetamine use disorder treatment.

BioCorRx Inc. President Louis C. Lucido has significantly increased his holdings of company stock through a series of issuances related to service agreements, director fees, and debt exchanges.

BioCorRx Inc.'s CEO and CFO, Lourdes Felix, has been granted a substantial number of company shares, reflecting her ongoing commitment and expanded role within the pharmaceutical company.

Louis C. Lucido, a director, 10% owner, and President of BioCorRx Inc., reports the acquisition of 44,220 shares of common stock on June 28, 2024, due to director and executive service agreements.

Director Luisa Ingargiola received shares of BioCorRx Inc. as compensation for her services, according to a recent SEC filing.

Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., acquired 10,204 shares of common stock on June 28, 2024, as part of her director compensation agreement.

Louis C. Lucido, a director, 10% owner, and President of BioCorRx Inc., acquired 22,831 shares of common stock on May 31, 2024, as part of his Executive Service Agreement.